Prostate cancer (PC) remains the most commonly diagnosed malignant disease in men worldwide (121). At present, PD-1/PD-L1 immunocheckpoint inhibitors have brought significant clinical benefits to some patients with PC. This evidence concerns the gene PDCD1 and pachyonychia congenita.